

IMPAIRED IMMUNE METABOLISM IN SEPSIS

1 Impaired peripheral mononuclear cell metabolism in patients at risk of developing 2 sepsis: A cohort study

3

4 Velma Herwanto, MD^{1,2,3*}, Ya Wang, PhD^{2,4*}, Maryam Shojaei, PhD^{2,4#}, Alamgir Khan,
5 PhD^{5#}, Kevin Lai, MD^{6&}, Amith Shetty, MD PhD^{1,6&}, Stephen Huang, PhD^{4&}, Tracy Chew,
6 PhD^{7&}, Sally Teoh, RN^{4&}, Marek Nalos, MD PhD^{4&}, Mandira Chakraborty, MD PhD^{4&},
7 Anthony S. McLean, Prof MD^{1,4&}, Benjamin MP. Tang, MD PhD^{1,2,4*}

8

9 1. The University of Sydney School of Medicine, NSW, Australia

10 2. Centre for Immunology and Allergy Research, the Westmead Institute for Medical
11 Research, NSW, Australia

12 3. Tarumanagara University, Faculty of Medicine, Jakarta, Indonesia

13 4. Department of Intensive Care Medicine, Nepean Hospital, NSW, Australia

14 5. Australian Proteome Analysis Facility, Macquarie University, NSW, Australia

15 6. Department of Emergency Medicine, Westmead Hospital, NSW, Australia

16 7. Sydney Informatics Hub, Core Research Facilities, The University of Sydney, NSW,
17 Australia

18

19 Corresponding author:

20 E-mail: vher6289@uni.sydney.edu.au (VH)

21 +62-8161820408

22

23 *These authors contributed equally to this work

24 #These authors also contributed equally to this work

25 &These authors also contributed equally to this work

26

27 **Abstract**

28 **Purpose**

29 Dysregulated immune response is a key driver of disease progression in sepsis and known to
30 be associated with impaired cellular metabolism. This association has been studied mostly in
31 the late stage sepsis patients. Here, we investigate whether such impairment in cellular
32 metabolism is present in uncomplicated infection patients who do not develop sepsis.

33 **Methods**

34 Forty sepsis (fulfilled Sepsis-3 criteria) and 27 uncomplicated infection patients were
35 recruited from the emergency department along with 20 healthy volunteers. Whole blood was
36 collected for measurement of gene expression, cytokine levels and cellular metabolic
37 functions (including mitochondrial respiration, oxidative stress and apoptosis).

38 **Results**

39 Our analysis revealed the impairment of mitochondrial respiration in uncomplicated infection
40 and sepsis patients (p value <0.05), with greater degree of impairment noted in the
41 established sepsis. The impairment was significantly correlated with increased mitochondrial
42 oxidative stress level; the latter was increased in uncomplicated infection and more so in
43 established sepsis patients. Further analysis revealed that the oxidative stress level correlated
44 significantly with cytokine level (tumor necrosis factor- α) and gene expression levels (CYCS,
45 TP53, SLC24A24 and TSPO).

46 **Conclusions**

47 These findings suggest that impaired immune cell metabolism is present in infection patients
48 without presenting sepsis, thereby opening potential window for early diagnosis and
49 intervention (e.g. antioxidant therapy) in such patients.

50 **Keywords:** cellular metabolism, mitochondrial respiration, glycolysis, oxidative stress,
51 apoptosis, peripheral blood mononuclear cells, leukocyte, sepsis, uncomplicated infection,
52 emergency department

53 **Introduction**

54 Sepsis is one of the most significant disease burdens in the world (1). A better understanding
55 of sepsis disease mechanism is urgently needed to facilitate development of new therapies.
56 Several pathophysiological mechanisms are involved, including endothelial dysfunction,
57 coagulopathy and dysregulated immune response (2). Among these, dysregulated immune
58 response is thought to play the most critical role in sepsis (3). The dysregulated immune
59 response in sepsis is characterized by impaired innate and adaptive immune responses; both
60 of which have been shown to strongly correlate with poor patient outcomes (4, 5).

61

62 It has been demonstrated that impaired cellular metabolism contributes to the dysregulated
63 immune response in sepsis. The impaired cellular metabolism includes reduced cellular
64 oxygen utilization and reduced ATP production (6-8). A number of studies in sepsis patients
65 have confirmed that these impairments are associated with increased organ failures and
66 reduced survival (9, 10).

67

68 Recent studies sought to identify defective pathways that are associated with impaired
69 cellular metabolism in peripheral blood mononuclear cell (PBMC) of sepsis patients (11, 12).
70 These studies have identified several defective cellular pathways such as inhibited
71 mitochondrial complex activity and oxygen consumption, and reduced ATP production
72 across different sepsis populations (13, 14). However, these studies share a common
73 limitation; they were conducted in patients with established sepsis or in the late stage of
74 sepsis. Therefore, it is uncertain whether impaired cellular metabolism is present prior to the
75 development of sepsis.

76

77 In this study, we sought to measure cellular metabolic state of PBMC in infection phase by
78 studying peripheral blood samples from patients who present to emergency department with
79 suspected infections, in whom sepsis is yet to develop. The overall goal of the study is to
80 detect early changes in the metabolic profile of circulating immune cells in the infection
81 patients and compare them to that of patients who later develop sepsis.

82

83

84 **Material and methods**

85 **Subjects recruitment**

86 This study was approved by Human Research Ethics Committee at our institution (reference
87 number HREC/18/WMEAD/67). Patients were recruited from the emergency department
88 (ED) at Westmead Hospital, New South Wales, Australia, between February 2018 and July
89 2019. Written informed consent was obtained from all subjects recruited. Inclusion criteria:
90 subjects were eligible if they aged 18 years or older; presented to the ED within the last 24
91 hours with infection, defined as either (1) positive pathogen identification in any body fluids
92 sampled for microbiological culture, or (2) a suspicion of infection (as determined by treating
93 physician) and received antibiotics. Exclusion criteria: (1) decision not to actively treat or
94 resuscitate the patient at admission; and (2) inability to consent the patient.

95

96


97 **Case definitions**

98 The study participants were assigned into sepsis or uncomplicated infection groups, based on
99 their Sequential Organ Failure Assessment (SOFA) score on admission (≥ 2 and < 2 ,
100 respectively) in accordance with the international consensus definition of sepsis (“Sepsis-3”)

101 (15, 16). Healthy volunteers who did not have infection or any pre-existing comorbidities
102 were recruited as controls.

103 Fig 1 illustrates the workflow of experiment.

104



105

106 **Fig 1.** Experiment workflow of the study

107

108

109 **Gene expression profiling**

110 **RNA extraction**

111 Two and a half millilitres of whole blood, which was collected into PAXgene Blood RNA
112 tube (BD Biosciences), was allowed to stand at room temperature for 2 hours, followed by
113 storage at -20°C for 24 hours. Thereafter, the tubes were transferred to -80°C for long term
114 storage. Total RNA was extracted using PAXgene Blood RNA Kit (QIAGEN) following the

115 manufacturer's protocol. Quantity and integrity of purified RNA were determined by the
116 RNA integrity number (RIN) using TapeStation (Agilent Technologies Inc.).

117 **Gene expression by NanoString[®] Technology**

118 Gene expression was measured using Nanostring nCounter[®] Elements[™] TagSet
119 (NanoString[®] Technologies Inc) preselected for mitochondrial biogenesis and function panel.
120 The panel includes 90 human genes and 6 housekeeping genes (Table S1). One hundred
121 nanograms of RNA from samples with RIN ≥ 7.0 was used for setting up the hybridization
122 reaction. A standard nCounter Prep Station was set up on the workstation for post-
123 hybridization processing. After which, sample cartridge was removed, sealed and loaded into
124 the Digital Analyzer to be scanned. Data resolution was set to high (280 images per sample).

125

126

127 **Gene expression data analyses**

128 nCounter data files (RCC files) were imported into the nSolver[™] analysis software v4.0
129 (NanoString Technologies) for quality control and raw mRNA abundance frequencies
130 analysis. Quality control was performed with the built-in negative and positive controls
131 following recommendations by NanoString Technologies. Raw data was normalized against
132 the geometric mean of 6 housekeeping genes included in the codeset. The expression level
133 was presented as fractional difference. It was calculated by dividing the difference between
134 the pooled expression values of patient and of healthy control, with pooled expression values
135 of healthy control. Pathway analysis was performed with Reactome Pathway Portal version
136 3.2 (17).

137

138

139

140

141 **Measurement of serum cytokines**

142 Whole blood collected in tube without anticoagulant was allowed to clot for 30 minutes to 1
143 hour at room temperature before centrifugation at 1,600 x g for 15 minutes at room
144 temperature. Supernatant was collected and stored at -80°C for further analyses.

145

146 Concentrations of cytokines were measured using the Bio-Plex Pro™ Human Cytokine
147 Screening 6-Plex Panel (Bio-Rad Laboratories) according to the manufacturer's protocol.

148 Analytes measured were interleukin 1 beta (IL-1 β), interleukin 4 (IL-4), interleukin 6 (IL-6),
149 interleukin 10 (IL-10), tumour necrosis factor alpha (TNF- α) and interferon gamma (IFN- γ).

150 Briefly, thawed serum samples were centrifuged at 10,000 x g for 10 minutes at 4°C to
151 remove cells. Fifty microliters of the duplicated serial-diluted standards and serum samples
152 were added to 96-well plate which contained the pre-washed antibody coated microbeads.

153 The plate was sealed, followed by incubation at room temperature for 1 hour with shaking at

154 850 rotations per minute under dark. The plate was then washed 3 times with Bio-Plex Pro II

155 magnetic plate washer and incubated with detection antibody for 30 minutes followed by 3

156 times washes and incubation with streptavidin-PE for 10 minutes at room temperature under

157 dark. All the liquids were delivered to the assay plate using a robotic platform (epMotion

158 5075, Eppendorf). The plate was read with the Bio-Plex 200 system using the Bio-Plex

159 manager v6.1 software.

160

161

162 **Measurement of cellular metabolism**

163 Agilent Seahorse XF Analyser was used to measure two key parameters: oxygen

164 consumption rate (OCR) and extracellular acidification rate (ECAR). These parameters

165 reflect effectiveness of mitochondrial respiration (OCR) and glycolysis (ECAR), which
166 provides an alternative energy pathway to mitochondrial respiration.

167 **Sample collection and preparation**

168 Whole blood sample was collected from healthy controls or study participants into tubes
169 containing anticoagulant EDTA. Peripheral blood mononuclear cells were isolated from the
170 whole blood using Ficoll. Isolated PBMCs were cryopreserved in freezing medium (fetal
171 bovine serum (FBS) with 10% DMSO) and stored in Vapor Phase liquid nitrogen tank until
172 further analyses.

173

174 **Cellular metabolism assay**

175 On the day of the assay, PBMCs were thawed and washed in RPMI + 10% FBS, and finally
176 resuspended in Seahorse XF Assay Medium and seeded onto microplate pre-coated with
177 Corning[®] Cell-Tak Cell and Tissue Adhesive (Bio-Strategy Pty Ltd) at 5×10^5 cells per well.
178 Each sample was analysed at least in triplicate. Metabolic profiling of PBMC was assessed
179 with the use of cell mito stress test kit (Agilent Technologies, Inc.), which includes three
180 drugs – oligomycin, carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) and
181 rotenone/ antimycin A. These drugs were pre-titrated and 2 μ M oligomycin, 2 μ M FCCP and
182 0.5 μ M rotenone/antimycin A were used for our assays. Sequential injections of these drugs
183 allowed the calculations of parameters related to mitochondrial respiration, including basal
184 respiration, maximal respiration, spare respiratory capacity and ATP production (18).

185

186 Data was analysed using the Wave Desktop software version 2.6. To normalize the data with
187 cell number, total protein amount was quantified at the completion of the XF assay using
188 Bradford protein assay kit (Bio-Rad) after cells in the wells were lysed with lysis buffer (10
189 mM Tris, pH 7.4, 0.1% Triton X-100) (19).

190

191

192 **Measurement of Oxidative Stress**

193 **Total cellular reactive oxygen species (ROS)**

194 To detect total cellular ROS, cells were stained with 2',7' – dichlorofluorescein diacetate
195 (DCFDA) Cellular ROS Detection Assay Kit (abcam) according to manufacturer's protocol.
196 Briefly, thawed PBMCs, resuspended in RPMI + 10% FBS, were allowed to rest for 2 hours
197 before staining with 20 μ M DCFDA for 30 minutes in 37°C CO₂ incubator. Stained cells
198 were subjected to analyses by BD FACs CantoII flow cytometer (BD Biosciences).
199 Application setting was applied each time before analyses. Data was analysed using FlowJo
200 v10 (BD Biosciences). Results were expressed as median fluorescence intensity (MFI) after
201 subtracting background from unstained samples.

202

203 **Mitochondrial superoxide**

204 To quantify mitochondrial superoxide, cells were stained with MitoSOX™ Red
205 (Invitrogen) according to manufacturer's protocol. Briefly, thawed PBMCs were washed and
206 resuspended in Hank's Balanced Salt Solution with calcium and magnesium (HBSS/Ca/Mg),
207 followed by staining with 5 μ M MitoSOX™ Red for 10 minutes in 37°C CO₂ incubator.
208 After staining, cells were washed twice and resuspended in HBSS/Ca/Mg, which were then
209 subjected to flow cytometry analyses as above.

210

211

212 **Measurement of apoptosis**

213 Cell apoptosis was quantified using Annexin V-FITC Apoptosis Detection Kit (abcam)
214 according to manufacturer's protocol. Cells were washed and resuspended in 1x binding
215 buffer, followed by staining with Annexin V-FITC and propidium iodide (PI). Stained cells
216 were subjected to flow cytometry analyses as above. The Annexin V positive and PI negative
217 cells were assigned as apoptotic cells.

218

219

220 **Statistical analysis and data visualization**

221 All statistical analyses were performed using SPSS version 25 (IBM) and GraphPad Prism 8.
222 For the normally distributed data, analyses were conducted using parametric test. For data
223 that was not normally distributed, data transformation was performed and was then subjected
224 to parametric test. If the transformation was not successful to normalise the data, the non-
225 parametric test was used. Graphs were generated using GraphPad Prism 8. Heatmap was
226 created using Morpheus software from Broad Institute
227 (<https://software.broadinstitute.org/morpheus>) .

228

229

230 **Results**

231 **Patients characteristics**

232 Demographic and clinical characteristics of patients are summarized in Table 1. There was no
233 significant difference in baseline characteristics between uncomplicated infection and sepsis
234 groups except for age ($p = 0.002$) and number of patients with existing comorbidities ($p =$
235 0.015). The average age of sepsis group was higher than that of uncomplicated infection
236 group (means 69 vs 56). Twenty healthy samples were recruited as controls, twelve (60%) of

237 them were male. Their median age was 59 (28 – 72) years old. Sepsis patients had higher C-
 238 reactive protein (CRP) and lactate levels as well as lower platelet count when compared to
 239 the uncomplicated infection.

240 **Table 1. Patients Demographic and Clinical Characteristics (n = 67)**

Characteristics	Uncomplicated Infection	Sepsis	P value
N (%)	27 (40.3)	40 (59.7)	
Age – yr	56.4 ± 18.12	69.1 ± 13.83	0.002
Male sex – no. (total no., %)	19 (70.4)	20 (50)	0.099
Source of infection			
Respiratory tract (%)	12 (44.4)	20 (50)	0.6551
Urinary tract (%)	4 (14.8)	12 (30)	0.1554
Abdominal, liver and biliary tract (%)	5 (18.5)	5 (12.5)	0.5022
Skin and soft tissue (%)	4 (14.8)	5 (12.5)	0.7881
Cardiovascular (%)	0 (0)	1 (2.5)	0.4113
Bone and joint (%)	1 (3.7)	1 (2.5)	0.7787
Unknown	2 (7.4)	1 (2.5)	0.3450
Comorbidities (%)	21 (77.8)	39 (97.5)	0.0150
Cardiovascular disease (%)	15 (55.6)	30 (75)	0.0997
Respiratory disease (%)	7 (25.9)	13 (32.5)	0.5654
Diabetes mellitus (%)	6 (22.2)	15 (37.5)	0.1887
Malignancy (%)	4 (14.8)	13 (32.5)	0.1050
Chronic kidney disease (%)	3 (11.1)	6 (15)	0.6485
Septic shock (%)	NA	10 (25.0)	NA
ICU admission (%)	0 (0)	9 (22.5)	0.0086
Hospital readmission – 28 day (%)	2 (7.4)	3 (7.5)	0.9879
Length of stay (day)	5 (1-68)	8 (1-106)	0.073
In-hospital mortality (%)	0 (0)	3 (7.5)	0.1484
Improving SOFA score on 3-5 days (%)	8/9 (88.9)	15/17 (88.2)	0.9585
Leukocyte count (x10 ⁹ /L)	12.5 ± 3.72	14.6 ± 8.62	0.188
Neutrophil count (x10 ⁹ /L)	10.0 ± 3.44	12.3 ± 8.17	0.124
Lymphocyte count (x10 ⁹ /L)	1.3 (0.5-5.1)	0.9 (0.2-4.2)	0.053
Monocyte count (x10 ⁹ /L)	0.7 (0.2-2.5)	0.9 (0.0-4.0)	0.453
Platelet (x10 ⁹ /L)	222 (136-701)	187 (43-414)	0.038
CRP (mg/L)	43 (3-295)	118 (3-390)	0.026
Lactate (mmol/L)	1.45 (0.8-2.9), n = 18	2 (0.4-6.5), n = 34	0.017
Procalcitonin (ng/mL)	0.1, n = 1	3.3 (0.1-212.3), n = 14	NA
Positive culture			

From source of infection (%)	11/24 (45.8)	20/37 (54.1)	0.5299
From blood (%)	6/21 (28.6)	13/32 (40.6)	0.3775


241 NA not available

242

243 **Serum cytokines' level are not significantly different between**
244 **uncomplicated infection and sepsis patients**

245 Infection/ sepsis was associated with changes in immune cell functions. We therefore sought
246 to determine if the levels of serum cytokines can reflect changes in immune cell functions
247 during the development of sepsis. In keeping with current literature (20), several
248 inflammatory cytokines were higher in both uncomplicated infection and sepsis groups when
249 compared to healthy controls (Fig 2). Serum levels of IL-10 and TNF- α were significantly
250 higher in sepsis group than healthy controls but no difference was observed between sepsis
251 and uncomplicated infection. Similarly, IL-6 level was higher in uncomplicated infection/
252 sepsis patients compared to healthy controls but again no difference was observed between
253 sepsis and uncomplicated infection.

254



255

256 **Fig 2.** Cytokine levels in healthy control/ HC (n = 12), uncomplicated infection/ I (n = 20)

257 and sepsis/ S (n = 31). Sepsis demonstrated the highest cytokine levels in IL-6, IL-10 and

258 TNF- α . Comparison between groups were performed by Kruskal-Wallis test followed by

259 Dunn's multiple comparison test.

260

261

262 **Downregulations of mitochondrial function-related genes are**

263 **more prominent in sepsis patients**

264 Having found that inflammatory cytokines did not distinguish between uncomplicated

265 infection and sepsis, we next proceeded to investigate whether gene-expression profiling

266 could distinguish between such patients. As an initial explorative step, we performed gene

267 expression profiling in the first 29 patients, as well as 11 healthy controls, recruited into the
268 study (Supplementary results, S1-S2 Tables).


269

270 In these experiments, 29 out of a total of 90 genes showed differential expression (FDR
271 <0.05) across three groups – healthy controls, uncomplicated infection and sepsis groups
272 (Figure 3A). From these 29 genes, 17 genes were significantly downregulated in infected/
273 sepsis patients when compared to healthy controls (Figure 3B). Of these 17 genes, 13 genes
274 were downregulated in the sepsis group but not in the uncomplicated infection groups. The
275 remaining 4 genes were also downregulated in the uncomplicated infection. Twelve genes
276 showed upregulation in infected/ sepsis patients compared to healthy controls (Figure 3B). Of
277 those genes, 5 genes were upregulated in uncomplicated infection as well as in sepsis group.
278 The other 7 genes were upregulated only in sepsis group.

279


280

281



282

283 **Fig 3A.** Heat map demonstrated 29 differentially expressed genes in log₂-counts. The
284 samples were grouped using semi-supervised clustering. Each sample is labelled by colour
285 according to the clinical condition (performed on a subset of 10 healthy controls, 14
286 uncomplicated infection and 15 sepsis subjects).



287

288 **Fig 3B.** The differentially expressed genes (FDR <0.05) in uncomplicated infection (n = 14)
289 and sepsis patients (n = 15) relative to healthy controls' (n = 10). Function of each gene is
290 indicated by colour (e.g. regulations on mitochondrial function, ROS production and
291 apoptosis cell death). Twenty genes were expressed differently in sepsis. Comparison
292 between groups were performed by one-way ANOVA followed by Benjamini-Yakutieli
293 False Discovery Rate method.


294

295

296 **Impaired mitochondrial function is observed in uncomplicated** 297 **infection and sepsis**

298 Having discovered the differences in gene expression related to mitochondrial pathway
299 between uncomplicated infection and sepsis, we were to confirm it by measuring

300 mitochondrial function of PBMC. Parameters related to mitochondrial functions including
301 basal respiration, maximal respiration, spare respiratory capacity and ATP production
302 reduced significantly in sepsis when compared to healthy control group (Figure 4 A-D).
303 When the sepsis was compared to uncomplicated infection, maximal respiration, spare
304 respiratory capacity and ATP production were significantly lower in sepsis group. Besides
305 mitochondrial dysfunction, we also observed a reduced basal ECAR in sepsis when compared
306 to healthy control (Figure 4E).
307



308
309 **Fig 4.** Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) on
310 subjects with gene expression data: 4A. basal respiration, 4B. maximal respiration, 4C. spare
311 capacity, 4D. ATP production, 4E. basal ECAR in healthy control/ HC (n = 10),
312 uncomplicated infection/ I (n = 14) and sepsis/ S (n = 15) group. Comparison between groups
313 were performed by one-way ANOVA followed by Tukey's multiple comparison test.

314

315 Notably, there were 20 mitochondrial-related genes which were differentially expressed in
316 those with sepsis but not in uncomplicated infection patients (Figure 3B). This finding points
317 to a potential difference in leukocyte biology between uncomplicated infection and sepsis.

318

319 Having confirmed the evidence of impaired cellular metabolism in the above 29 patients, we
320 next proceeded to measure the same metabolic parameters for the entire cohort (67 patients
321 and 20 controls). These measurements again confirmed significant impairment and a trend
322 towards impaired mitochondrial functions in sepsis and uncomplicated infection patients,
323 respectively (Supplementary results, S1 Fig). The following findings described hereafter
324 were performed on the entire cohort.

325


326

327 **Increased mitochondrial oxidative stress is observed in** 328 **uncomplicated infection and sepsis patients**

329 Previous research shows that increased mitochondrial oxidative stress is associated with
330 impaired mitochondrial function in circulating leukocytes (21). Our results support this, as
331 we observed increased mitochondrial superoxide level, as measured by MitoSOX, in both
332 uncomplicated infection and sepsis groups when compared to healthy controls (Figure 5A).

333 There was also a trend towards increased total cellular ROS (measured by DCFDA) in
334 uncomplicated infection and sepsis when compared to healthy controls (Figure 5B) even
335 though they were not statistically significant.

336



337

338 **Fig 5.** MitoSOX (5A) and DCFDA (5B) staining in healthy control (HC), uncomplicated
339 infection (I) and sepsis (S). N for MitoSOX = HC (20), I (24), S (36), respectively; n for
340 DCFDA = HC (20), I (26), S (37), respectively. For MitoSOX dataset, comparison between
341 groups was performed with Kruskal-Wallis test followed by Dunn's multiple comparison.
342 For DCFDA dataset, comparison between groups was made using one-way ANOVA
343 followed by Tukey's multiple comparison.

344

345

346

347

348

349 **Mitochondrial oxidative stress correlates with gene expression**
350 **level, serum cytokine level and bacteremia**

351 Previous study showed that mitochondrial oxidative stress may be increased by several
352 factors in infection/ sepsis (22). These factors include increased systemic inflammation (e.g.
353 proinflammatory cytokines), pathogen factor (presence of bacteremia) and transcriptional
354 factor (gene expression). To investigate the possible roles of those factors, we performed a
355 correlation analysis between mitochondrial superoxide levels and: serum cytokine levels,
356 bacteremia and mitochondrial ROS-related genes including Cytochrome C/ CYCS (electron
357 transport chain), Tumor Protein P53/ TP53 (maintains cellular redox status), Solute Carrier
358 Family 25 Member 24/ SLC25A24 (buffers calcium level in mitochondrial matrix) and
359 Translocator Protein/ TSPO (translocator protein for release of proapoptotic mitochondrial
360 component).

361

362 Our analyses showed that mitochondrial superoxide level correlated with increased
363 proinflammatory cytokine TNF- α ($r = 0.330$, $p < 0.05$) but not with IL-6 and IL-10 ($p > 0.05$).
364 Similarly, mitochondrial superoxide level correlated with expression levels of CYCS, TP53,
365 SLC24A24 and TSPO ($r_s = -0.4926, -0.4422, 0.4382, 0.4835$, respectively; $p < 0.05$).
366 Additionally, a higher oxidative stress level was observed in patients with as compared to
367 those without bacteremia ($p < 0.05$) (S2 Fig).

368

369

370

371

372 **Impact of increased oxidative stress on leukocyte function and** 373 **survival**

374 With increased levels of mitochondrial superoxide observed in both uncomplicated infection
375 and sepsis groups, we evaluated the association of this increase with leukocyte mitochondrial
376 functions. Our analyses revealed a significant inverse correlation between an increased
377 mitochondrial superoxide level and mitochondrial function ($p < 0.05$) (S3 Fig). The findings
378 were consistent across all parameters as measured by our cellular metabolism assay.

379

380 Existing literature shows both impaired mitochondrial function (23) and increased intra-
381 mitochondrial oxidative stress (24) may lead to the activation of apoptotic pathways.
382 However, we did not observe any significant increase in apoptosis measured by Annexin V
383 and PI in PBMCs from either the uncomplicated infection or the sepsis group (S4 Fig).

384

385

386 **Discussion**

387 Currently, it remains unclear whether defective cellular metabolism exists in circulating
388 leukocytes of patients who are in the early stage sepsis. Our study provide evidence that the
389 defect is present in patients who are infected and more so in those who progress to sepsis.
390 The impaired cellular metabolism is evident across several platforms including gene-
391 expression profiling, cellular metabolism analyses and intra-mitochondrial reactive oxygen
392 species measurement.

393

394 Although we do not have direct evidence to implicate oxidative stress as a causal factor in the
395 impairment of cellular metabolism, we do observe a moderate correlation between the degree

396 of mitochondrial oxidative stress and the extent of cellular respiration impairment, i.e.
397 increasing mitochondrial oxidative stress correlates with worsening of cellular respiration.
398 The increase in mitochondrial oxidative stress level is associated with higher
399 proinflammatory cytokine, bacteremia and gene dysregulation. Inflammatory cytokine (25)
400 and dysregulation of genes (26) are known to be associated with oxidative stress and, in
401 general, reduced cellular respiration (27). The presence of bacteremia, as shown in this study,
402 is also associated with increased oxidative stress since bacterial infection is the trigger of
403 ROS production (28).

404

405 The relationship between proinflammatory cytokine, oxidative stress and impaired
406 mitochondrial function is complex. The levels of proinflammatory cytokines significantly
407 show correlation with oxidative stress and impaired mitochondrial function. Mitochondrial
408 oxidative stress itself can further activate inflammatory response through the production of
409 signalling molecules that propagate cellular dysfunction (29). Therefore, it is likely that
410 changes in systemic inflammation milieu, intra-mitochondrial oxidative stress and cellular
411 respiration are intricately linked. It is beyond the scope of our study to delineate such
412 complex relationship; clearly, additional mechanistic studies are needed in the future.

413

414 We also observe that in uncomplicated infection patients, the circulating immune cells do not
415 shift the ATP production to glycolysis. Existing literatures indicate that host cells expect to
416 switch their main metabolism into glycolysis when stressed (8, 30). The lack of such a switch
417 might be because immune cells may utilize pathways alternative to glycolysis (31) to
418 generate more ATP. Additionally, different immune cell subsets prefer to use different
419 dominant type of metabolism, e.g. naïve T cells are dependent on mitochondrial respiration
420 as their primary metabolic pathway while activated T cells exhibit higher glycolysis (32).

421 Further studies are needed to address this issue, as by using glycolysis-specific assay in
422 purified cell subsets.

423 This study demonstrates the lack of cytokine use as a marker for staging sepsis patients (33).
424 The increase of cytokines found in this study could not distinguish sepsis from the
425 uncomplicated infection, on which the routine laboratories, such as CRP, lactate level and
426 platelet count, could discriminate those severities better. This indicates the need to develop
427 more specific yet practical markers that enable us to stage infection patients according to
428 their risk severities.

429

430 Our findings have some important therapeutic implications. The observed increased
431 mitochondrial oxidative stress in uncomplicated infection could contribute to later
432 mitochondrial dysfunction. This observation should be stretched in future mechanistic
433 studies. If the relationship between mitochondrial oxidative stress and mitochondrial
434 impairment is confirmed, it may open up opportunity for early intervention (e.g.
435 mitochondrial-targeted antioxidant) for patients in early stage of infection.

436

437 We have used multiple modalities from transcriptomic to functional analyses to investigate
438 the change in mitochondrial and immune function which has strengthened this research.
439 Additionally, this study included infection patients from ED instead of the “established”
440 sepsis from intensive care unit (ICU). Therefore, we could observe metabolic changes in
441 broader spectrum of disease rather than simply comparing the changes between severe
442 disease and the normal end. In regard to it, the finding of impaired cellular metabolism in
443 uncomplicated infection consequently suggests that past biomarkers developed in the
444 critically ill, i.e. ICU, patients might have low relevance in ED setting.

445

446 Some limitations are notified in this study. First, the study participants are highly
447 heterogenous in comorbidities and age. Those factors should be put into consideration when
448 interpreting the result, i.e. patients with diabetes mellitus or older age might have different
449 basal oxidative stress level. Secondly, most of the study participants have favorable outcome,
450 i.e. minimal number of mortality. In the same manner, the analysis is ideally explored in
451 patients with poor outcome, as the result might be variable from those with good prognosis.
452 Thirdly, total ROS is not an ideal assay to measure oxidative stress since, technically,
453 intermediate radical will falsely amplify the fluorescence intensity (34, 35). The non-
454 significant signal of total cellular ROS might be explained by this issue.

455

456 Surprisingly, we did not observe increased cell death in this study, despite significant
457 increase in mitochondrial oxidative stress levels and impairment of mitochondrial function.
458 Similar findings are also noted in previous studies (36, 37) who showed no, or slight, increase
459 in apoptosis from flow cytometry measurement in sepsis patients. This could be because
460 dying cells are rapidly removed by reticuloendothelial system and, therefore, are less likely to
461 appear in circulating blood (38). Another possible explanation could be that dying cells are
462 not captured during sample processing procedure. To address this issue, early marker of
463 apoptosis can be used in future study (39, 40).

464

465 In conclusion, impairment of cellular metabolism, presented mainly as mitochondrial
466 dysfunction, is evident in the immune cells of infection patients without presenting sepsis.
467 Oxidative stress, along with inflammation and transcription regulation, might be a potential
468 initiator, amplifier or victim to explain the impairment.

469

470

471

472

473 **Acknowledgement**

474 We gratefully acknowledge the contribution of Joey Lai, PhD, Stephen Schibeci, Nicole
475 Fewings, PhD and Lawrence Ong, PhD for their input in data analysis; Sydney Informatics
476 Hub, a Core Research Facility of the University of Sydney; and Indonesia Endowment Fund
477 for Education (LPDP) for the grant support. No compensation was provided for those
478 assistances.

479

480

481 **References**

- 482 1. Rudd KE, Kissoon N, Limmathurotsakul D, Bory S, Mutahunga B, Seymour CW, et
483 al. The global burden of sepsis: barriers and potential solutions. *Crit Care*.
484 2018;22:232.
- 485 2. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. *BMJ*.
486 2016;353:i1585.
- 487 3. Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution and
488 long-term outcome. *Immunol Rev*. 2016;274(1):330-53.
- 489 4. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies
490 reduce mortality? *J Clin Invest*. 2016;126(1):23-31.
- 491 5. Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP. Sepsis-induced T cell
492 immunoparalysis: the ins and outs of impaired T cell immunity. *J Immunol*.
493 2018;200(5):1543-53.

- 494 6. Boulos M, Astiz ME, Barua RS, Osman M. Impaired mitochondrial function induced
495 by serum from septic shock patients is attenuated by inhibition of nitric oxide
496 synthase and poly(ADP-ribose) synthase. *Crit Care Med.* 2003;31(2):353-8.
- 497 7. Pearlstein DP, Ali MH, Mungai PT, Hynes KL, Gewertz BL, Schumacker PT. Role of
498 mitochondrial oxidant generation in endothelial cell responses to hypoxia.
499 *Arterioscler Thromb Vasc Biol.* 2002;22(4):566-73.
- 500 8. Cheng S-C, Scicluna BP, Arts RJW, Gresnigt MS, Lachmandas E, Giamarellos-
501 Bourboulis EJ, et al. Broad defects in the energy metabolism of leukocytes underlie
502 immunoparalysis in sepsis. *Nature Immunol.* 2016;17(4):406-13.
- 503 9. Carré JE, Orban J-C, Re L, Felsmann K, Iffert W, Bauer M, et al. Survival in critical
504 illness is associated with early activation of mitochondrial biogenesis. *Am J Resp Crit*
505 *Care Med.* 2010;182(6):745-51.
- 506 10. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association
507 between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet.*
508 2002;360:219-23.
- 509 11. Garrabou G, Morén C, López S, Tobías E, Cardellach F, Miró Ò, et al. The effects of
510 sepsis on mitochondria. *J Infect Dis.* 2012;205(3):392-400.
- 511 12. Japiassú AM, Santiago AP, d'Avila JC, Garcia-Souza LF, Galina A, Faria-Neto HCC,
512 et al. Bioenergetic failure of human peripheral blood monocytes in patients with
513 septic shock is mediated by reduced F1Fo adenosine-5'-triphosphate synthase activity.
514 *Crit Care Med.* 2011;39(5):1056-63.
- 515 13. Merz TM, Pereira AJ, Schürch R, Schefold JC, Jakob SM, Takala J, et al.
516 Mitochondrial function of immune cells in septic shock: a prospective observational
517 cohort study. *PLoS One.* 2017;12(6):e0178946.

- 518 14. Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernández-Jiménez
519 E, et al. Human monocytes undergo functional re-programming during sepsis
520 mediated by Hypoxia-Inducible Factor-1 α . *Immunity*. 2015;42(3):484-98.
- 521 15. Bone RC, Balk RA, Cerra FB, Dellinger P, Fein AM, Knaus WA, et al. Definitions
522 for sepsis and organ failure and guidelines for the use of innovative therapies in
523 sepsis. ACCP/ SCCM Consensus Conference. *Chest*. 1992;101(6):1481-3.
- 524 16. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et
525 al. The Third International Consensus Definitions for Sepsis and Septic Shock
526 (Sepsis-3). *JAMA*. 2016;315(8):801–10.
- 527 17. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The
528 Reactome pathway knowledgebase. *Nucleic Acids Res*. 2018;46(D1):D649-55.
- 529 18. Agilent Technologies, Inc. Agilent Seahorse XF Cell Mito Stress Test Kit. User guide
530 kit 103015-100 [Internet]. 2019 [cited 2020 May 31]. Available from:
531 <https://www.agilent.com>
- 532 19. Dranka BP, Benavides GA, Diers AR, Giordano S, Zelickson BR, Reily C, et al.
533 Assessing bioenergetic function in response to oxidative stress by metabolic profiling.
534 *Free Radic Biol Med*. 2011;51(9):1621-35.
- 535 20. Matsumoto H, Ogura H, Shimizu K, Ikeda M, Hirose T, Matsuura H, et al. The
536 clinical importance of a cytokine network in the acute phase of sepsis. *Sci Rep*.
537 2018;8:13995.
- 538 21. Chen Y, Zhou Z, Min W. Mitochondria, Oxidative Stress and Innate Immunity. *Front*
539 *Physiol*. 2018;9:1487.
- 540 22. Li X, Fang P, Mai J, Choi ET, Wang H, Yang X-f. Targeting mitochondrial reactive
541 oxygen species as novel therapy for inflammatory diseases and cancers. *J Hematol*
542 *Oncol*. 2013;6:19.

- 543 23. Kushnareva Y, Newmeyer DD. Bioenergetics and cell death. *Ann N Y Acad Sci.*
544 2010;1201:50-7.
- 545 24. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways
546 by reactive oxygen species. *BBA Mol Cell Res.* 2016;1863(12):2977-92.
- 547 25. Lavieri R, Piccioli P, Carta S, Delfino L, Castellani P, Rubartelli A. TLR
548 costimulation causes oxidative stress with unbalance of proinflammatory and anti-
549 inflammatory cytokine production. *J Immunol.* 2014;192(11):5373-81.
- 550 26. Bime C, Zhou T, Wang T, Slepian MJ, Garcia JGN, Hecker L. Reactive oxygen
551 species-associated molecular signature predicts survival in patients with sepsis. *Pulm*
552 *Circ.* 2016;26(2):196-201.
- 553 27. Nucci LA, Santos SS, Brunialti MK, Sharma NK, Machado FR, Assunção M, et al.
554 Expression of genes belonging to the interacting TLR cascades, NADPH-oxidase and
555 mitochondrial oxidative phosphorylation in septic patients. *PLoS One.*
556 2017;12(2):e0172024.
- 557 28. Ivanov AV, Bartosch B, Isaguliantz MG. Oxidative stress in infection and consequent
558 disease. *Oxid Med Cell Longev.* 2017;2017:3496043.
- 559 29. Vringer E, Tait SWG. Mitochondria and inflammation: cell death heats up. *Front Cell*
560 *Dev Biol.* 2019;7:100.
- 561 30. Everts B, Amiel E, Windt GJWvd, Freitas TC, Chott R, Yarasheski KE, et al.
562 Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic
563 cells. *Blood.* 2012;120(7):1422-31.
- 564 31. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence.
565 *Immunity.* 2013;38(4):633-43.

- 566 32. Angajala A, Lim S, Phillips JB, Kim J-H, Yates C, You Z, et al. Diverse roles of
567 mitochondria in immune responses: novel insights into immuno-metabolism. *Front*
568 *Immunol.* 2018;9:1605.
- 569 33. Lvovschi V, Arnaud L, Parizot C, Freund Y, Juillien G, Ghillani-Dalbin P, et al.
570 Cytokine profiles in sepsis have limited relevance for stratifying patients in the
571 emergency department: A prospective observational study. *PLoS One.*
572 2011;6(12):e28870.
- 573 34. Kalyanaraman B, Darley-USmar V, Davies KJA, Dennery PA, Forman HJ, Grisham
574 MB, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes:
575 challenges and limitations. *Free Radic Biol Med.* 2012;52:1-6.
- 576 35. Dikalov SI, Harrison DG. Methods for detection of mitochondrial and cellular
577 reactive oxygen species. *Antioxid Redox Signal.* 2014;20(2):372-82.
- 578 36. Turrel-Davin F, Guignant C, Lepape A, Mouglin B, Monneret G, Venet F.
579 Upregulation of the pro-apoptotic genes BID and FAS in septic shock patients. *Crit*
580 *Care.* 2010;14:R133.
- 581 37. Adrie C, Bachelet M, Vayssier-Taussat M, Russo-Marie F, Bouchaert I, Adib-Conquy
582 M, et al. Mitochondrial membrane potential and apoptosis peripheral blood
583 monocytes in severe human sepsis. *Am J Respir Crit Care Med.* 2001;164:389-95.
- 584 38. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE. Apoptosis
585 in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-
586 deficient mice. *Crit Care Med.* 1997;25:1298–307.
- 587 39. Duplessis C, Gregory M, Frey K, Bell M, Truong L, Schully K, et al. Evaluating the
588 discriminating capacity of cell death (apoptotic) biomarkers in sepsis. *J Intensive*
589 *Care.* 2018;6:72.

590 40. Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstem C, Weitz J, et al. Cell death
591 serum biomarkers are early predictors for survival in severe septic patients with
592 hepatic dysfunction. Crit Care. 2009;13:R93.

593

594 **Supporting information**

595 **Supplementary results**

596 Downregulation of mitochondrial function-related genes is observed in sepsis

597 Impaired mitochondrial function is observed in uncomplicated infection and sepsis

598 **Supplementary tables**

599 **S1 Table.** List of genes on NanoString's mitochondrial biogenesis and function panel

600 **S2 Table.** Demographic and clinical characteristic of overall subjects vs subset of subjects
601 for gene expression analysis

602 **Supplementary figures**

603 **S1 Fig.** Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) on
604 subjects with gene expression data

605 **S2 Fig.** MitoSOX level in non-bacteremia and bacteremia subjects

606 **S3 Fig.** Correlation matrix between MitoSOX level and mito stress test parameters

607 **S4 Fig.** Annexin V⁺ and propidium iodide⁻ population in healthy control, uncomplicated
608 infection and sepsis